| 1 |
Morris H, DeWolf S, Robins H, et al. Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients[J]. Sci Transl Med, 2015, 7(272): 272ra10.
|
| 2 |
Zimmerer JM, Horne PH, Fisher MG, et al. Unique CD8+ T cell-mediated immune responses primed in the liver[J]. Transplantation, 2016, 100(9): 1907-1915.
|
| 3 |
Feng S, Bucuvalas J. Tolerance after liver transplantation: Where are we？[J]. Liver Transpl, 2017, 23(12): 1601-1614.
|
| 4 |
Sánchez-Fueyo A, Whitehouse G, Grageda N, et al. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation[J]. Am J Transplant, 2020, 20(4): 1125-1136.
|
| 5 |
Whitehouse GP, Hope A, Sanchez-Fueyo A. Regulatory T-cell therapy in liver transplantation[J]. Transpl Int, 2017, 30(8): 776-784.
|
| 6 |
Vaikunthanathan T, Safinia N, Boardman D, et al. Regulatory T cells: tolerance induction in solid organ transplantation[J]. Clin Exp Immunol, 2017, 189(2): 197-210.
|
| 7 |
Halliday N, Williams C, Kennedy A, et al. CD86 is a selective CD28 ligand supporting FoxP3+ regulatory T cell homeostasis in the presence of high levels of CTLA-4[J]. Front Immunol, 2020, 11: 600000.
|
| 8 |
Heidari F, Ramezani A, Erfani N, et al. Indoleamine 2, 3-dioxygenase: A professional immunomodulator and its potential functions in immune related diseases[J]. Int Rev Immunol, 2020: 1-18.
|
| 9 |
Tang Q, Vincenti F. Transplant trials with Tregs: perils and promises[J]. J Clin Invest, 2017, 127(7): 2505-2512.
|
| 10 |
Safinia N, Grageda N, Scottà C, et al. Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells[J]. Front Immunol, 2018, 9: 354.
|
| 11 |
Ko MK, Shao H, Kaplan HJ, et al. CD73+ dendritic cells in cascading Th17 responses of experimental autoimmune uveitis-induced mice[J]. Front Immunol, 2020, 11: 601272.
|
| 12 |
Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance[J]. Immunity, 2007, 27(4): 635-646.
|
| 13 |
Okoye I, Xu L, Motamedi M, et al. Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors[J]. J Immunother Cancer, 2020, 8(2): e001849.
|
| 14 |
Ronca V, Wootton G, Milani C, et al. The immunological basis of liver allograft rejection[J]. Front Immunol, 2020, 11: 2155.
|
| 15 |
Alvarez-Salazar EK, Cortés-Hernández A, Arteaga-Cruz S, et al. Large-scale generation of human allospecific induced Tregs with functional stability for use in immunotherapy in transplantation[J]. Front Immunol, 2020, 11: 375.
|
| 16 |
Tran LM, Thomson AW. Detection and monitoring of regulatory immune cells following their adoptive transfer in organ transplantation[J]. Front Immunol, 2020, 11: 614578.
|
| 17 |
Golshayan D, Jiang S, Tsang J, et al. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance[J]. Blood, 2007, 109(2): 827-835.
|
| 18 |
Ferreira LMR, Muller YD, Bluestone JA, et al. Next-generation regulatory T cell therapy[J]. Nat Rev Drug Discov, 2019, 18(10): 749-769.
|
| 19 |
Del Papa B, Ruggeri L, Urbani E, et al. Clinical-grade-expanded regulatory T cells prevent graft-versus-host disease while allowing a powerful T cell-dependent graft-versus-leukemia effect in murine models[J]. Biol Blood Marrow Transplant, 2017, 23(11): 1847-1851.
|
| 20 |
Veerapathran A, Pidala J, Beato F, et al. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly[J]. Blood, 2011, 118(20): 5671-5680.
|
| 21 |
Lee K, Nguyen V, Lee KM, et al. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy[J]. Am J Transplant, 2014, 14(1): 27-38.
|
| 22 |
Noyan F, Zimmermann K, Hardtke-Wolenski M, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor[J]. Am J Transplant, 2017, 17(4): 917-930.
|
| 23 |
MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor[J]. J Clin Invest, 2016, 126(4): 1413-1424.
|
| 24 |
Boardman DA, Philippeos C, Fruhwirth GO, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection[J]. Am J Transplant, 2017, 17(4): 931-943.
|
| 25 |
Ward NC, Yu A, Moro A, et al. IL-2/CD25: A long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells [J]. J Immunol, 2018, 201(9): 2579-2592.
|
| 26 |
Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease[J]. Sci Transl Med, 2013, 5(179): 179ra43.
|
| 27 |
Whitehouse G, Gray E, Mastoridis S, et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors[J]. Proc Natl Acad Sci U S A, 2017, 114(27): 7083-7088.
|
| 28 |
Thomson AW, Humar A, Lakkis FG, et al. Regulatory dendritic cells for promotion of liver transplant operational tolerance: Rationale for a clinical trial and accompanying mechanistic studies[J]. Hum Immunol, 2018, 79(5): 314-321.
|
| 29 |
Rickert CG, Markmann JF. Current state of organ transplant tolerance[J]. Curr Opin Organ Transplant, 2019, 24(4): 441-450.
|
| 30 |
Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis[J]. Nat Med, 2014, 20(1): 62-68.
|
| 31 |
Tripathi D, Cheekatla SS, Paidipally P, et al. C-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice[J]. Sci Rep, 2018, 8(1): 3310.
|
| 32 |
Chen Z, Barbi J, Bu S, et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3[J]. Immunity, 2013, 39(2): 272-285.
|
| 33 |
Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology, 2016, 64(2): 632-643.
|
| 34 |
Du X, Chang S, Guo W, et al. Progress in liver transplant tolerance and tolerance inducing cellular therapies [J]. Front Immunol, 2020, 11: 1326.
|
| 35 |
Mathew JM, H-Voss J, LeFever A, et al. A phase Ⅰ clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants[J]. Sci Rep, 2018, 8(1): 7428.
|
| 36 |
Chandran S, Tang Q, Sarwal M, et al. Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants[J]. Am J Transplant, 2017, 17(11): 2945-2954.
|
| 37 |
Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up[J]. Clin Immunol, 2014, 153(1): 23-30.
|
| 38 |
Di Ianni M, Falzetti F, Carotti A, et al. Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation[J]. Best Pract Res Clin Haematol, 2011, 24(3): 459-466.
|
| 39 |
Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse[J]. Blood, 2014, 124(4): 638-644.
|
| 40 |
Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn′s disease[J]. Gastroenterology, 2012, 143(5): 1207-1217.
|